Cargando…

Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study

BACKGROUND: Liver transplantation (LT) is an effective therapy for acute-on-chronic liver failure (ACLF) but is limited by organ shortages. We aimed to identify an appropriate score for predicting the survival benefit of LT in HBV-related ACLF patients. METHODS: Hospitalized patients with acute dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Peng, Liang, Xi, Luo, Jinjin, Li, Jiaqi, Xin, Jiaojiao, Jiang, Jing, Shi, Dongyan, Lu, Yingyan, Hassan, Hozeifa Mohamed, Zhou, Qian, Hao, Shaorui, Zhang, Huafen, Wu, Tianzhou, Li, Tan, Yao, Heng, Ren, Keke, Guo, Beibei, Zhou, Xingping, Chen, Jiaxian, He, Lulu, Yang, Hui, Hu, Wen, Ma, Shiwen, Li, Bingqi, You, Shaoli, Xin, Shaojie, Chen, Yu, Li, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923183/
https://www.ncbi.nlm.nih.gov/pubmed/36793753
http://dx.doi.org/10.1016/j.lanwpc.2022.100638
_version_ 1784887682854289408
author Li, Peng
Liang, Xi
Luo, Jinjin
Li, Jiaqi
Xin, Jiaojiao
Jiang, Jing
Shi, Dongyan
Lu, Yingyan
Hassan, Hozeifa Mohamed
Zhou, Qian
Hao, Shaorui
Zhang, Huafen
Wu, Tianzhou
Li, Tan
Yao, Heng
Ren, Keke
Guo, Beibei
Zhou, Xingping
Chen, Jiaxian
He, Lulu
Yang, Hui
Hu, Wen
Ma, Shiwen
Li, Bingqi
You, Shaoli
Xin, Shaojie
Chen, Yu
Li, Jun
author_facet Li, Peng
Liang, Xi
Luo, Jinjin
Li, Jiaqi
Xin, Jiaojiao
Jiang, Jing
Shi, Dongyan
Lu, Yingyan
Hassan, Hozeifa Mohamed
Zhou, Qian
Hao, Shaorui
Zhang, Huafen
Wu, Tianzhou
Li, Tan
Yao, Heng
Ren, Keke
Guo, Beibei
Zhou, Xingping
Chen, Jiaxian
He, Lulu
Yang, Hui
Hu, Wen
Ma, Shiwen
Li, Bingqi
You, Shaoli
Xin, Shaojie
Chen, Yu
Li, Jun
author_sort Li, Peng
collection PubMed
description BACKGROUND: Liver transplantation (LT) is an effective therapy for acute-on-chronic liver failure (ACLF) but is limited by organ shortages. We aimed to identify an appropriate score for predicting the survival benefit of LT in HBV-related ACLF patients. METHODS: Hospitalized patients with acute deterioration of HBV-related chronic liver disease (n = 4577) from the Chinese Group on the Study of Severe Hepatitis B (COSSH) open cohort were enrolled to evaluate the performance of five commonly used scores for predicting the prognosis and transplant survival benefit. The survival benefit rate was calculated to reflect the extended rate of the expected lifetime with vs. without LT. FINDINGS: In total, 368 HBV-ACLF patients received LT. They showed significantly higher 1-year survival than those on the waitlist in both the entire HBV-ACLF cohort (77.2%/52.3%, p < 0.001) and the propensity score matching cohort (77.2%/27.6%, p < 0.001). The area under the receiver operating characteristic curve (AUROC) showed that the COSSH-ACLF II score performed best (AUROC 0.849) at identifying the 1-year risk of death on the waitlist and best (AUROC 0.864) at predicting 1-year outcome post-LT (COSSH-ACLFs/CLIF-C ACLFs/MELDs/MELD-Nas: AUROC 0.835/0.825/0.796/0.781; all p < 0.05). The C-indexes confirmed the high predictive value of COSSH-ACLF IIs. Survival benefit rate analyses showed that patients with COSSH-ACLF IIs 7–10 had a higher 1-year survival benefit rate from LT (39.2%–64.3%) than those with score <7 or >10. These results were prospectively validated. INTERPRETATION: COSSH-ACLF IIs identified the risk of death on the waitlist and accurately predicted post-LT mortality and survival benefit for HBV-ACLF. Patients with COSSH-ACLF IIs 7–10 derived a higher net survival benefit from LT. FUNDING: This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (No. 81830073, No. 81771196) and the National Special Support Program for High-Level Personnel Recruitment (Ten-thousand Talents Program).
format Online
Article
Text
id pubmed-9923183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99231832023-02-14 Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study Li, Peng Liang, Xi Luo, Jinjin Li, Jiaqi Xin, Jiaojiao Jiang, Jing Shi, Dongyan Lu, Yingyan Hassan, Hozeifa Mohamed Zhou, Qian Hao, Shaorui Zhang, Huafen Wu, Tianzhou Li, Tan Yao, Heng Ren, Keke Guo, Beibei Zhou, Xingping Chen, Jiaxian He, Lulu Yang, Hui Hu, Wen Ma, Shiwen Li, Bingqi You, Shaoli Xin, Shaojie Chen, Yu Li, Jun Lancet Reg Health West Pac Articles BACKGROUND: Liver transplantation (LT) is an effective therapy for acute-on-chronic liver failure (ACLF) but is limited by organ shortages. We aimed to identify an appropriate score for predicting the survival benefit of LT in HBV-related ACLF patients. METHODS: Hospitalized patients with acute deterioration of HBV-related chronic liver disease (n = 4577) from the Chinese Group on the Study of Severe Hepatitis B (COSSH) open cohort were enrolled to evaluate the performance of five commonly used scores for predicting the prognosis and transplant survival benefit. The survival benefit rate was calculated to reflect the extended rate of the expected lifetime with vs. without LT. FINDINGS: In total, 368 HBV-ACLF patients received LT. They showed significantly higher 1-year survival than those on the waitlist in both the entire HBV-ACLF cohort (77.2%/52.3%, p < 0.001) and the propensity score matching cohort (77.2%/27.6%, p < 0.001). The area under the receiver operating characteristic curve (AUROC) showed that the COSSH-ACLF II score performed best (AUROC 0.849) at identifying the 1-year risk of death on the waitlist and best (AUROC 0.864) at predicting 1-year outcome post-LT (COSSH-ACLFs/CLIF-C ACLFs/MELDs/MELD-Nas: AUROC 0.835/0.825/0.796/0.781; all p < 0.05). The C-indexes confirmed the high predictive value of COSSH-ACLF IIs. Survival benefit rate analyses showed that patients with COSSH-ACLF IIs 7–10 had a higher 1-year survival benefit rate from LT (39.2%–64.3%) than those with score <7 or >10. These results were prospectively validated. INTERPRETATION: COSSH-ACLF IIs identified the risk of death on the waitlist and accurately predicted post-LT mortality and survival benefit for HBV-ACLF. Patients with COSSH-ACLF IIs 7–10 derived a higher net survival benefit from LT. FUNDING: This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (No. 81830073, No. 81771196) and the National Special Support Program for High-Level Personnel Recruitment (Ten-thousand Talents Program). Elsevier 2022-11-10 /pmc/articles/PMC9923183/ /pubmed/36793753 http://dx.doi.org/10.1016/j.lanwpc.2022.100638 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Li, Peng
Liang, Xi
Luo, Jinjin
Li, Jiaqi
Xin, Jiaojiao
Jiang, Jing
Shi, Dongyan
Lu, Yingyan
Hassan, Hozeifa Mohamed
Zhou, Qian
Hao, Shaorui
Zhang, Huafen
Wu, Tianzhou
Li, Tan
Yao, Heng
Ren, Keke
Guo, Beibei
Zhou, Xingping
Chen, Jiaxian
He, Lulu
Yang, Hui
Hu, Wen
Ma, Shiwen
Li, Bingqi
You, Shaoli
Xin, Shaojie
Chen, Yu
Li, Jun
Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study
title Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study
title_full Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study
title_fullStr Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study
title_full_unstemmed Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study
title_short Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study
title_sort predicting the survival benefit of liver transplantation in hbv-related acute-on-chronic liver failure: an observational cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923183/
https://www.ncbi.nlm.nih.gov/pubmed/36793753
http://dx.doi.org/10.1016/j.lanwpc.2022.100638
work_keys_str_mv AT lipeng predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT liangxi predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT luojinjin predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT lijiaqi predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT xinjiaojiao predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT jiangjing predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT shidongyan predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT luyingyan predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT hassanhozeifamohamed predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT zhouqian predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT haoshaorui predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT zhanghuafen predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT wutianzhou predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT litan predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT yaoheng predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT renkeke predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT guobeibei predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT zhouxingping predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT chenjiaxian predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT helulu predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT yanghui predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT huwen predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT mashiwen predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT libingqi predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT youshaoli predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT xinshaojie predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT chenyu predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT lijun predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy
AT predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy